Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Narrative) (Details)

v3.2.0.727
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
 6 Months Ended
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Accounting Policies [Abstract]      
Derivative liabilities $ 63,000   $ 0
Lymphoseek license revenue   $ 2,000,000  
Deferred revenue recognition period 2 years    
New Accounting Pronouncement, Early Adoption, Effect      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Discounts on notes payable, current $ 35,000    
Discounts on notes payable, noncurrent 55,000    
Scenario, Previously Reported      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Deferred debt issuance cost     $ 90,000
Reported Value Measurement [Member]      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Fair value of notes payable 59,200,000    
Estimate of Fair Value Measurement [Member]      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Fair value of notes payable $ 68,000,000